Clinuvel Pharmaceuticals Limited
OTC: CLVLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Jacques Wolgen
- Employees
- 109
- Headquarters
- Melbourne, Australia
- IPO year
- 2009
- Market cap
- $307.5M
- Website
- https://www.clinuvel.com
Loading CLVLF…
Loading profile data…Frequently asked questions about CLVLF
What does Clinuvel Pharmaceuticals Limited (CLVLF) do?
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the Un...
Where does CLVLF trade?
Clinuvel Pharmaceuticals Limited (CLVLF) trades on the Other OTC.
What sector is CLVLF in?
Clinuvel Pharmaceuticals Limited (CLVLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clinuvel Pharmaceuticals Limited?
Philippe Jacques Wolgen is the chief executive officer of Clinuvel Pharmaceuticals Limited (CLVLF).
Where is Clinuvel Pharmaceuticals Limited headquartered?
Clinuvel Pharmaceuticals Limited is headquartered in Australia.
Does CLVLF pay a dividend?
Yes — Clinuvel Pharmaceuticals Limited (CLVLF) paid a trailing twelve-month dividend of USD 0.03 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did CLVLF go public?
Clinuvel Pharmaceuticals Limited (CLVLF) completed its initial public offering in 2009.